Cargando…

Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022

As atherosclerosis begins in childhood, early diagnosis and treatment of familial hypercholesterolemia (FH) is considered necessary. The basic diagnosis of pediatric FH (under 15 years of age) is based on hyper-low-density lipoprotein (LDL) cholesterolemia and a family history of FH; however, in thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Harada-Shiba, Mariko, Ohtake, Akira, Sugiyama, Daisuke, Tada, Hayato, Dobashi, Kazushige, Matsuki, Kota, Minamino, Tetsuo, Yamashita, Shizuya, Yamamoto, Yukiyo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Atherosclerosis Society 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164603/
https://www.ncbi.nlm.nih.gov/pubmed/36682777
http://dx.doi.org/10.5551/jat.CR006
_version_ 1785038105036718080
author Harada-Shiba, Mariko
Ohtake, Akira
Sugiyama, Daisuke
Tada, Hayato
Dobashi, Kazushige
Matsuki, Kota
Minamino, Tetsuo
Yamashita, Shizuya
Yamamoto, Yukiyo
author_facet Harada-Shiba, Mariko
Ohtake, Akira
Sugiyama, Daisuke
Tada, Hayato
Dobashi, Kazushige
Matsuki, Kota
Minamino, Tetsuo
Yamashita, Shizuya
Yamamoto, Yukiyo
author_sort Harada-Shiba, Mariko
collection PubMed
description As atherosclerosis begins in childhood, early diagnosis and treatment of familial hypercholesterolemia (FH) is considered necessary. The basic diagnosis of pediatric FH (under 15 years of age) is based on hyper-low-density lipoprotein (LDL) cholesterolemia and a family history of FH; however, in this guideline, to reduce overlooked cases, “probable FH” was established. Once diagnosed with FH or probable FH, efforts should be made to promptly provide lifestyle guidance, including diet. It is also important to conduct an intrafamilial survey, to identify family members with the same condition. If the level of LDL-C remains above 180 mg/dL, drug therapy should be considered at the age of 10. The first-line drug should be statin. Evaluation of atherosclerosis should be started using non-invasive techniques, such as ultrasound. The management target level is an LDL-C level of less than 140 mg/dL. If a homozygous FH is suspected, consult a specialist and determine the response to pharmacotherapy with evaluating atherosclerosis. If the response is inadequate, initiate lipoprotein apheresis as soon as possible.
format Online
Article
Text
id pubmed-10164603
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Japan Atherosclerosis Society
record_format MEDLINE/PubMed
spelling pubmed-101646032023-05-09 Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022 Harada-Shiba, Mariko Ohtake, Akira Sugiyama, Daisuke Tada, Hayato Dobashi, Kazushige Matsuki, Kota Minamino, Tetsuo Yamashita, Shizuya Yamamoto, Yukiyo J Atheroscler Thromb Correspondence As atherosclerosis begins in childhood, early diagnosis and treatment of familial hypercholesterolemia (FH) is considered necessary. The basic diagnosis of pediatric FH (under 15 years of age) is based on hyper-low-density lipoprotein (LDL) cholesterolemia and a family history of FH; however, in this guideline, to reduce overlooked cases, “probable FH” was established. Once diagnosed with FH or probable FH, efforts should be made to promptly provide lifestyle guidance, including diet. It is also important to conduct an intrafamilial survey, to identify family members with the same condition. If the level of LDL-C remains above 180 mg/dL, drug therapy should be considered at the age of 10. The first-line drug should be statin. Evaluation of atherosclerosis should be started using non-invasive techniques, such as ultrasound. The management target level is an LDL-C level of less than 140 mg/dL. If a homozygous FH is suspected, consult a specialist and determine the response to pharmacotherapy with evaluating atherosclerosis. If the response is inadequate, initiate lipoprotein apheresis as soon as possible. Japan Atherosclerosis Society 2023-05-01 2023-01-20 /pmc/articles/PMC10164603/ /pubmed/36682777 http://dx.doi.org/10.5551/jat.CR006 Text en 2023 Japan Atherosclerosis Society https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/)
spellingShingle Correspondence
Harada-Shiba, Mariko
Ohtake, Akira
Sugiyama, Daisuke
Tada, Hayato
Dobashi, Kazushige
Matsuki, Kota
Minamino, Tetsuo
Yamashita, Shizuya
Yamamoto, Yukiyo
Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022
title Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022
title_full Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022
title_fullStr Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022
title_full_unstemmed Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022
title_short Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022
title_sort guidelines for the diagnosis and treatment of pediatric familial hypercholesterolemia 2022
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164603/
https://www.ncbi.nlm.nih.gov/pubmed/36682777
http://dx.doi.org/10.5551/jat.CR006
work_keys_str_mv AT haradashibamariko guidelinesforthediagnosisandtreatmentofpediatricfamilialhypercholesterolemia2022
AT ohtakeakira guidelinesforthediagnosisandtreatmentofpediatricfamilialhypercholesterolemia2022
AT sugiyamadaisuke guidelinesforthediagnosisandtreatmentofpediatricfamilialhypercholesterolemia2022
AT tadahayato guidelinesforthediagnosisandtreatmentofpediatricfamilialhypercholesterolemia2022
AT dobashikazushige guidelinesforthediagnosisandtreatmentofpediatricfamilialhypercholesterolemia2022
AT matsukikota guidelinesforthediagnosisandtreatmentofpediatricfamilialhypercholesterolemia2022
AT minaminotetsuo guidelinesforthediagnosisandtreatmentofpediatricfamilialhypercholesterolemia2022
AT yamashitashizuya guidelinesforthediagnosisandtreatmentofpediatricfamilialhypercholesterolemia2022
AT yamamotoyukiyo guidelinesforthediagnosisandtreatmentofpediatricfamilialhypercholesterolemia2022